WHO strongly advises against antibody treatments for Covid-19 patients

Two antibody drugs that work by neutralising the SARS-CoV-2 virus' spike protein (foreground) are no longer recommended for treating Covid-19 due to their lack of effectiveness against current viral variants, including Omicron. — AFP/US NIH

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with Covid-19, said a World Health Organization (WHO) Guideline Development Group of international experts in The BMJ medical journal on Sept 16 (2022).

These drugs work by binding to the SARS-CoV-2 spike protein, neutralising the virus’s ability to infect cells.